Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biofrontera (BFRI) EBT (2020 - 2025)

Biofrontera has reported EBT over the past 6 years, most recently at $5.6 million for Q4 2025.

  • For Q4 2025, EBT rose 503.15% year-over-year to $5.6 million; the TTM value through Dec 2025 reached -$10.5 million, up 40.75%, while the annual FY2025 figure was -$10.5 million, 40.74% up from the prior year.
  • EBT for Q4 2025 was $5.6 million at Biofrontera, up from -$6.6 million in the prior quarter.
  • Over five years, EBT peaked at $5.6 million in Q4 2025 and troughed at -$16.0 million in Q3 2021.
  • A 5-year average of -$4.3 million and a median of -$3.9 million in 2021 define the central range for EBT.
  • Biggest five-year swings in EBT: crashed 7612.77% in 2021 and later surged 503.15% in 2025.
  • Year by year, EBT stood at -$14.5 million in 2021, then skyrocketed by 80.8% to -$2.8 million in 2022, then soared by 226.44% to $3.5 million in 2023, then crashed by 139.74% to -$1.4 million in 2024, then surged by 503.15% to $5.6 million in 2025.
  • Business Quant data shows EBT for BFRI at $5.6 million in Q4 2025, -$6.6 million in Q3 2025, and -$5.3 million in Q2 2025.